e18526 Background: Independent studies have suggested follicular lymphoma (FL) patients who are homozygous for 158V and 131H alleles in the FcγRIIIa and FcγRIIa genes respectively, achieve higher response rates with rituximab monotherapy. We previously reported complete response rate (CR) of 89% in 60 untreated patients with stage II-IV symptomatic or bulky FL who received short-course CHOP-rituximab (R) x 3 cycles followed by ibritumomab tiuxetan (IT) and extended R as first-line treatment (SA Jacobs, et al. Clin Cancer Res 2008) and presented follow-up results (DR Mehta, et al. ASCO 2010). This abstract reviews a subgroup of 32 such patients genotyped for these polymorphisms.
PMID: 28023272 [PubMed - in process]